Velpanat / Epclusa (sofosbuvir/velpatasvir) 400 mg/100 mg, Natco, India, generic Epclusa / Velpanat contains velpatasvir 100 mg and sofosbuvir 400 mg and is used for chronic hepatitis C. International medicine delivery within 4-5 days with storage conditions maintained. Payment on delivery. Order at +380996042415 via Viber or WhatsApp.
- Delivery of non-temperature-controlled medicines to Chisinau - $25.
Delivery of temperature-controlled medicines to Chisinau - $50.
Up to 5 packages can be sent per shipment. The price applies to one shipment. - Pickup from Odesafree
- Shipping within Ukraine by Nova Poshta at the carrier's rates.
Payment in UAH upon receipt of the order.
Delivery time
- Originator medicines: 5-7 days
- Generic medicines: 3-4 days
- Bank transfer to the settlement account after receiving the order
- Payment upon pickup in Odesa
Epclusa is a pan-genotypic combination intended for interferon-free therapy of HCV genotypes one to six.
Active substance:
Velpatasvir 100 mg and Sofosbuvir 400 mg
Manufacturer:
Gilead Sciences International Ltd, Cambridge
Generic manufacturer NATCO India
Indications:
Epclusa is used for treatment chronic hepatitis C for all virus genotypes (1-6) without cirrhosis, with compensated or decompensated liver cirrhosis (in combination with ribavirin).
Description:
One Epclusa tablet contains fixed doses of sofosbuvir (an NS5B polymerase inhibitor of the hepatitis C virus) and velpatasvir (an NS5A inhibitor) and is intended for the treatment of adult patients with chronic hepatitis C infected with the virus of all major genotypes (1, 2, 3, 4, 5 or 6).
Sofosbuvir, as you know, was developed and approved back in 2013, and velpatasvir appeared quite recently.
This is the first drug that allows treating patients with genotype 2 and 3 virus without the need to take ribavirin.
Dosage:
This is the first combination drug with a dosage regimen of one tablet once a day. Based on the FDA's conclusion, Epclusa is capable of combating all six genotypes of the hepatitis C virus; complete cure is guaranteed for 95% of patients.
In addition to the fact that the drug is intended for the treatment of all genotypes of HCV, a feature of the use of this combination is that without cirrhosis and with compensated cirrhosis (Child-Pugh class A), the duration of therapy is 12 weeks, without the use of ribavirin. For decompensated cirrhosis (class B and C), a double duration of 24 weeks and a combination with ribavirin are recommended.
Adverse reactions:
There is a risk of developing bradycardia when Epclusa is used in conjunction with Amiodarone and other direct-acting anti-hepatitis C drugs. The risk is especially high in patients taking beta blockers for cardiovascular disease and/or in patients with advanced liver disease. Cardiac monitoring is recommended for patients for whom there is no other alternative. If symptoms of brachycardia occur, you should immediately seek medical help.
The most common adverse reactions (≥10%) of Epclus are headache and fatigue; when used with Ribavirin in cases with decompensated cirrhosis, fatigue, anemia, nausea, headache, insomnia, diarrhea are noted.
Interaction with other drugs:
The use of Sofosbuvir and Velpatasvir is not recommended with drugs that are P-gp inducers and / or inducers CYP2B6, as these combinations may lead to a significant decrease in plasma levels of Sofosbuvir and Velpatasvir. Note that the solubility of Velpatasvir decreases as gastric pH increases and medications that increase gastric pH may decrease Velpatasvir concentrations; co-administration of proton pump inhibitors with Epclusa is also not recommended.
